Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during...

Area of Science:

• Dermatology
• Molecular Biology
• Angiogenesis Research

Background:

• Psoriasis is a chronic inflammatory skin condition characterized by abnormal angiogenesis.
• Vascular endothelial growth factor (VEGF) and plasminogen activator inhibitor-1 (PAI-1) are key regulators of angiogenesis.
• Their specific roles in psoriasis pathogenesis require further elucidation.

Purpose of the Study:

• To evaluate the levels of VEGF and PAI-1 in patients with psoriasis undergoing treatment.
• To assess the correlation between these molecules and disease severity.

Main Methods:

• Plasma samples and skin biopsies were collected from 16 psoriasis patients and 13 healthy controls.
• VEGF and PAI-1 plasma levels were measured using ELISA before and during 6 months of ranitidine treatment.
• Skin biopsy analysis assessed vessel counts, compared with Psoriasis Area and Severity Index (PASI) scores.

Main Results:

• Pre-treatment plasma levels of VEGF and PAI-1 were significantly higher in psoriasis patients than in controls.
• Treatment led to a significant decrease in both VEGF and PAI-1 levels.
• The reduction in these molecules correlated with improved PASI scores, although skin vessel density remained unchanged.

Conclusions:

• Elevated pre-treatment levels of VEGF and PAI-1 in psoriasis patients suggest their involvement in the disease.
• The observed decrease during treatment indicates a potential therapeutic target.
• Further research is warranted to fully understand the role of VEGF and PAI-1 in psoriasis pathogenesis.